<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39455652</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>In-silico evaluation of the T-cell based immune response against SARS-CoV-2 omicron variants.</ArticleTitle><Pagination><StartPage>25413</StartPage><MedlinePgn>25413</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25413</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75658-w</ELocationID><Abstract><AbstractText>During of COVID-19 pandemic, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has continuously evolved, resulting in the emergence of several new variants of concerns (VOCs) with numerous mutations. These VOCs dominate in various regions due to increased transmissibility and antibody evasion, potentially reducing vaccine effectiveness. Nonetheless, it remains uncertain whether the recent SARS-CoV-2 VOCs have the ability to circumvent the T cell immunity elicited by either COVID-19 vaccination or natural infection. To address this, we conducted in-silico analysis to examine the impact of VOC-specific mutations at the epitope level and T cell cross-reactivity with the ancestral SARS-CoV-2. According to the in-silico investigation, T cell responses triggered by immunization or prior infections still recognize the variants in spite of mutations. These variants are expected to either maintain their dominant epitope HLA patterns or bind with new HLAs, unlike the epitopes of the ancestral strain. Our findings indicate that a significant proportion of immuno-dominant CD8 + and CD4 + epitopes are conserved across all the variants, implying that existing vaccines might maintain efficacy against new variations. However, further in-vitro and in-vivo studies are needed to validate the in-silico results and fully elucidate immune sensitivities to VOCs.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Shivangi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bioinformatics and Data Management Group, ICMR-National Institute of Virology, Pune, Maharashtra, 411001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Diya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bioinformatics and Data Management Group, ICMR-National Institute of Virology, Pune, Maharashtra, 411001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherian</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bioinformatics and Data Management Group, ICMR-National Institute of Virology, Pune, Maharashtra, 411001, India. sarahcherian100@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>09/0698(13659)/2022-EMR-I</GrantID><Agency>Council of Scientific and Industrial Research, India</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="Y">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="Y">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39455652</ArticleId><ArticleId IdType="pmc">PMC11511884</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75658-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75658-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature579, 270–273 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Callender, L. A. et al. The impact of pre-existing comorbidities and therapeutic interventions on COVID-19. Front. Immunol.11, 1991 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437504</ArticleId><ArticleId IdType="pubmed">32903476</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID - Coronavirus Statistics. Worldometer. https://www.worldometers.info/coronavirus/.</Citation></Reference><Reference><Citation>Stern, A. &amp; Andino, R. Viral Evolution. in Viral Pathogenesis 233–240 (Elsevier, 2016). 10.1016/B978-0-12-800964-2.00017-3.</Citation></Reference><Reference><Citation>Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol.21, 361–379 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet.22, 757–773 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8447121</ArticleId><ArticleId IdType="pubmed">34535792</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, J. Y. &amp; Smith, D. M. SARS-CoV-2 variants of concern. Yonsei Med. J.62, 961 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542474</ArticleId><ArticleId IdType="pubmed">34672129</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto, S. P. et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr. Biol.31, R918–R929 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220957</ArticleId><ArticleId IdType="pubmed">34314723</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavda, V. P., Patel, A. B. &amp; Vaghasiya, D. D. SARS-CoV‐2 variants and vulnerability at the global level. J. Med. Virol.94, 2986–3005 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088647</ArticleId><ArticleId IdType="pubmed">35277864</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway, E. Heavily mutated Omicron variant puts scientists on alert. Nature600, 21–21 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34824381</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature603, 679–686 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature608, 593–602 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Desingu, P. A., Nagarajan, K. &amp; Dhama, K. Emergence of Omicron third lineage BA.3 and its importance. J. Med. Virol.94, 1808–1810 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015590</ArticleId><ArticleId IdType="pubmed">35043399</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature604, 553–556 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021018</ArticleId><ArticleId IdType="pubmed">35240676</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki, R. et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet. Infect. Dis.23, 30–32 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9729000</ArticleId><ArticleId IdType="pubmed">36495917</ArticleId></ArticleIdList></Reference><Reference><Citation>Araf, Y. et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J. Med. Virol.94, 1825–1832 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015557</ArticleId><ArticleId IdType="pubmed">35023191</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar, S. &amp; Isom, D. G. One Year of SARS-CoV-2: How much has the virus changed? Biology10, 91 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7911924</ArticleId><ArticleId IdType="pubmed">33530355</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing, E. et al. Dynamics of SARS-CoV-2 spike proteins in cell entry: Control elements in the amino-terminal domains. mBio12, e01590-21 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406164</ArticleId><ArticleId IdType="pubmed">34340537</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson, E. C. et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell184, 1171–1187e20 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7843029</ArticleId><ArticleId IdType="pubmed">33621484</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature602, 664–670 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9531318</ArticleId><ArticleId IdType="pubmed">35016195</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife9, e61312 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Triveri, A. et al. SARS-CoV-2 spike protein mutations and escape from antibodies: A computational model of Epitope loss in variants of concern. J. Chem. Inf. Model.61, 4687–4700 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8479857</ArticleId><ArticleId IdType="pubmed">34468141</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell185, 2422–2433e13 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science370, 1227–1230 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810037</ArticleId><ArticleId IdType="pubmed">33115920</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol.23, 186–193 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann, D. M. &amp; Boyton, R. J. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci. Immunol.5, eabd6160 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32680954</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan, L. J. et al. SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors. Cell. Rep.40, 111284 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9371981</ArticleId><ArticleId IdType="pubmed">35987196</ArticleId></ArticleIdList></Reference><Reference><Citation>Almendro-Vázquez, P., Laguna-Goya, R. &amp; Paz-Artal, E. Defending against SARS-CoV-2: The T cell perspective. Front. Immunol.14, 1107803 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9911802</ArticleId><ArticleId IdType="pubmed">36776863</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoletti, A., Le Bert, N., Qui, M. &amp; Tan, A. T. SARS-CoV-2-specific T cells in infection and vaccination. Cell. Mol. Immunol.18, 2307–2312 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8408362</ArticleId><ArticleId IdType="pubmed">34471260</ArticleId></ArticleIdList></Reference><Reference><Citation>Agerer, B. et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 + T cell responses. Sci. Immunol.6, eabg6461 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8224398</ArticleId><ArticleId IdType="pubmed">33664060</ArticleId></ArticleIdList></Reference><Reference><Citation>Motozono, C. et al. An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. 04.02.438288 Preprint at (2021). 10.1101/2021.04.02.438288 (2021).</Citation></Reference><Reference><Citation>Motozono, C. et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe29, 1124–1136e11 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8205251</ArticleId><ArticleId IdType="pubmed">34171266</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, D. et al. Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors. Nat. Commun.13, 19 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8748687</ArticleId><ArticleId IdType="pubmed">35013235</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolton, G. et al. Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. Cell185, 2936–2951e19 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279490</ArticleId><ArticleId IdType="pubmed">35931021</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai, V. et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell185, 1041–1051e6 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8810349</ArticleId><ArticleId IdType="pubmed">35202566</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretti, M. A. M., Galvani, R. G., Scherer, N. M., Farias, A. S. &amp; Boroni, M. In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8 + T cell reactivity and also signs of immune response escape. Infect. Genet. Evol.99, 105236 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824006</ArticleId><ArticleId IdType="pubmed">35149224</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, H. et al. Profiling CD8 + T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell. Rep.36, 109708 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8390359</ArticleId><ArticleId IdType="pubmed">34506741</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan, S., Mohkhedkar, M. &amp; Janakiraman, V. Mutations in spike protein T cell epitopes of SARS-COV-2 variants: plausible influence on vaccine efficacy. Biochim. et Biophys. Acta (BBA) - Mol. Basis Dis.1868, 166432 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9109158</ArticleId><ArticleId IdType="pubmed">35568352</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni, A. et al. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. Cell. Host Microbe29, 1076–1092 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139264</ArticleId><ArticleId IdType="pubmed">34237248</ArticleId></ArticleIdList></Reference><Reference><Citation>Parn, S., Savsani, K. &amp; Dakshanamurthy, S. SARS-CoV-2 Omicron (BA.1 and BA.2) specific novel CD8 + and CD4 + T cell epitopes targeting spike protein. ImmunoInformatics8, 100020 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9624113</ArticleId><ArticleId IdType="pubmed">36337685</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke, A. et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell. Rep. Med.2, 100204 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837622</ArticleId><ArticleId IdType="pubmed">33521695</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita, R. et al. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res.47, D339–D343 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324067</ArticleId><ArticleId IdType="pubmed">30357391</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhanda, S. K. et al. IEDB-AR: immune epitope database—analysis resource in 2019. Nucleic Acids Res.47, W502–W506 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602498</ArticleId><ArticleId IdType="pubmed">31114900</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangavarapu, K. et al. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Nat. Methods20, 512–522 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10399614</ArticleId><ArticleId IdType="pubmed">36823332</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu, Y. &amp; McCauley, J. G. I. S. A. I. D. Global initiative on sharing all influenza data—from vision to reality. Euro. Surveill. 22, 30494 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388101</ArticleId><ArticleId IdType="pubmed">28382917</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silva, T. I. et al. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. iScience24, 103353 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8552693</ArticleId><ArticleId IdType="pubmed">34729465</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmelot, M. E. et al. Omicron BA.1 mutations in SARS-CoV-2 spike lead to reduced T-cell response in vaccinated and convalescent individuals. Viruses14, 1570 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9318964</ArticleId><ArticleId IdType="pubmed">35891550</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur, S. et al. SARS-CoV-2 mutations and their impact on diagnostics, therapeutics and vaccines. Front. Med.9, 815389 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8902153</ArticleId><ArticleId IdType="pubmed">35273977</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan, S. et al. Ablation of CD8 + T cell recognition of an immunodominant epitope in SARS-CoV-2 omicron variants BA.1, BA.2 and BA.3. Nat. Commun.13, 6387 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9607807</ArticleId><ArticleId IdType="pubmed">36302758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao, D. et al. SARS-CoV‐2 omicron variant: Immune escape and vaccine development. MedComm3, e126 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8925644</ArticleId><ArticleId IdType="pubmed">35317190</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y., Zhi, H. &amp; Teng, Y. The outbreak of SARS-CoV‐2 omicron lineages, immune escape, and vaccine effectivity. J. Med. Virol.95, e28138 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538491</ArticleId><ArticleId IdType="pubmed">36097349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity52, 971–977e3 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196424</ArticleId><ArticleId IdType="pubmed">32413330</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremoni, M. et al. Humoral and Cellular Response of Frontline Health Care workers infected by SARS-CoV-2 in Nice, France: A prospective single-center cohort study. Front. Med.7, 608804 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7873459</ArticleId><ArticleId IdType="pubmed">33585509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan, A., Al-Ozairi, E., Al-Baqsumi, Z., Ahmad, R. &amp; Al-Mulla, F. Cellular and humoral immune responses in Covid-19 and immunotherapeutic approaches. ITT10, 63–85 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955763</ArticleId><ArticleId IdType="pubmed">33728277</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas, C. et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature600, 523–529 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348899</ArticleId><ArticleId IdType="pubmed">34634791</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke, A. et al. Impact of SARS-CoV-2 variants on the total CD4 + and CD8 + T cell reactivity in infected or vaccinated individuals. Cell. Rep. Med.2, 100355 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8249675</ArticleId><ArticleId IdType="pubmed">34230917</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature603, 488–492 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930768</ArticleId><ArticleId IdType="pubmed">35102311</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J. et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature603, 493–496 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930761</ArticleId><ArticleId IdType="pubmed">35102312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, Y. et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med.28, 472–476 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938268</ArticleId><ArticleId IdType="pubmed">35042228</ArticleId></ArticleIdList></Reference><Reference><Citation>Geers, D. et al. SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Sci. Immunol.6, eabj1750 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9268159</ArticleId><ArticleId IdType="pubmed">34035118</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, S. J. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl. J. Med.385, 1761–1773 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. (2004). https://www.ncbi.nlm.nih.gov/. Accessed on May 21, 2023.</Citation></Reference><Reference><Citation>Bui, H. H., Sidney, J., Li, W., Fusseder, N. &amp; Sette, A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinform.8, 361 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2233646</ArticleId><ArticleId IdType="pubmed">17897458</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynisson, B., Alvarez, B., Paul, S., Peters, B. &amp; Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res.48, W449–W454 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319546</ArticleId><ArticleId IdType="pubmed">32406916</ArticleId></ArticleIdList></Reference><Reference><Citation>Calis, J. J. A. et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput. Biol.9, e1003266 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3808449</ArticleId><ArticleId IdType="pubmed">24204222</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynisson, B. et al. Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data. J. Proteome Res.19, 2304–2315 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32308001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauri, M., Elli, T., Caviglia, G., Uboldi, G. &amp; Azzi, M. RAWGraphs: A Visualisation Platform to Create Open Outputs. in Proceedings of the 12th Biannual Conference on Italian SIGCHI Chap. 1–5ACM, Cagliari Italy. 10.1145/3125571.3125585 (2017).</Citation></Reference><Reference><Citation>Dhanda, S. K., Vir, P. &amp; Raghava, G. P. Designing of interferon-gamma inducing MHC class-II binders. Biol. Direct8, 30 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4235049</ArticleId><ArticleId IdType="pubmed">24304645</ArticleId></ArticleIdList></Reference><Reference><Citation>Doytchinova, I. A. &amp; Flower, D. R. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform.8, 4 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780059</ArticleId><ArticleId IdType="pubmed">17207271</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov, I., Bangov, I., Flower, D. R. &amp; Doytchinova, I. AllerTOP v.2—a server for in silico prediction of allergens. J. Mol. Model.20, 2278 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24878803</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, S. et al. In Silico Approach for Predicting toxicity of peptides and proteins. PLoS ONE8, e73957 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772798</ArticleId><ArticleId IdType="pubmed">24058508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins, M. R. et al. Protein Identification and Analysis Tools in the ExPASy Server. in 2-D Proteome Analysis Protocols112, 531–552 (Humana Press, New Jersey, 1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">10027275</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman, H. M. The protein data bank. Nucleic Acids Res.28, 235–242 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102472</ArticleId><ArticleId IdType="pubmed">10592235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhachoo, J. &amp; Beuming, T. Investigating protein–peptide interactions using the Schrödinger Computational suite. in Modeling Peptide-Protein Interactions (eds Schueler-Furman) vol 1561 235–254 (Springer New York, New York, NY, (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28236242</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmond Molecular Dynamics System, Schrödinger Release 2020-3, Shaw, D. E. &amp; Research New York, NY, 2020. Maestro-Desmond Interoperability Tools. Schrödinger. (2020). https://scholar.google.com/scholar_lookup?title=Desmond+Molecular+Dynamics+System,+D.+E.+Shaw+Research,+New+York,+NY,+2020.+Maestro-Desmond+Interoperability+Tools&amp;publication_year=2020.</Citation></Reference><Reference><Citation>Bui, H. H. et al. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinform.7, 153 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513259</ArticleId><ArticleId IdType="pubmed">16545123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, Z., Bogdan, P. &amp; Nazarian, S. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study. Sci. Rep.11, 3238 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7865008</ArticleId><ArticleId IdType="pubmed">33547334</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali, M. et al. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Sci. Rep.7, 9232 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5569093</ArticleId><ArticleId IdType="pubmed">28835708</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh, H., Jakhar, R. &amp; Sehrawat, N. Designing spike protein (S-Protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics. Heliyon6, e05528 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7667438</ArticleId><ArticleId IdType="pubmed">33225084</ArticleId></ArticleIdList></Reference><Reference><Citation>Baral, P. et al. Immunoinformatic screening of Marburgvirus epitopes and computational investigations of epitope-allele complexes. Int. Immunopharmacol.111, 109109 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35926269</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapin, N., Lund, O., Bernaschi, M. &amp; Castiglione, F. Computational immunology meets bioinformatics: The use of prediction tools for molecular binding in the simulation of the immune system. PLoS ONE5, e9862 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855701</ArticleId><ArticleId IdType="pubmed">20419125</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>